An endogenous inhibitor of microsomal mixed-function oxidases in homogenates of the southern armyworm (Prodenia eridania).
Ontology highlight
ABSTRACT:
SUBMITTER: Krieger RI
PROVIDER: S-EPMC1185499 | biostudies-other | 1970 Mar
REPOSITORIES: biostudies-other
Similar Datasets
Project description:A potent inhibitor of microsomal mixed-function oxidation reactions in insects had previously been isolated and partially purified from the gut contents of Prodenia eridania and shown to be associated with proteinase activity. Incubation of rat liver microsomal fraction with low concentrations of this inhibitor led to solubilization of NADPH-cytochrome c reductase, which was paralleled by the inactivation of reduction of cytochrome P-450 by NADPH and by the inhibition of NADPH-linked benzo[3,4]pyrene hydroxylation and aminopyrine demethylation. There was little or no effect on cytochromes b(5) and P-450, nor was the capacity of the latter catalyst to combine with exogenous substrates decreased. Contrary to the findings with NADPH, preincubation of microsomal fraction with the inhibitor did not cause a significant decrease in the rate of cytochrome P-450 reduction by NADH, supporting the assumption that different catalysts are involved in the electron transfer from NADH and NADPH to cytochrome P-450. The findings indicate the importance of taking the possible presence of endogenous inhibitors into consideration when evaluating low or absent mixed-function oxidation activities found in insect systems in vitro.
| S-EPMC1177157 | biostudies-other
Project description:1. Activity of 5-aminolaevulinate synthetase was measured in the midgut and other tissues of the last larval instar of the southern armyworm (Spodoptera eridania Cramer, formerly Prodenia eridania Cramer). 2. Optimum conditions for measuring the activity were established with respect to all variables involved and considerable differences from those reported for mammalian enzyme preparations were found. 3. Maximum activity (20 nmol/h per mg of protein) occurs 18-24 h after the fifth moult and thereafter decreases to trace amounts as the larvae age and approach pupation. 4. Synthetase activity was rapidly induced by oral administration (in the diet) of pentamethylbenzene, phenobarbital, diethyl 1,4-dihydro-2,4,6-trimethylpyridine-3, 5-dicarboxylate, and 2-allyl-2-isopropylacetamide. 5. Puromycin inhibited the induction of synthetase by pentamethylbenzene. 6. Induction of 5-aminolaevulinate synthetase correlated well with the induction of microsomal N-demethylation of p-chloro-N-methylaniline, except for phenobarbital, which induced the microsomal oxidase relatively more than the synthetase.
| S-EPMC1165708 | biostudies-other
Project description:An intraperitoneal dose of CS(2) (500mg/kg) to male rats resulted in loss of liver microsomal mixed-function-oxidase activity (85% loss of biphenyl 4-hydroxylase), followed by denaturation of liver cytochrome P-450 to cytochrome P-420, and degradative loss of both cytochromes (50% loss). Losses of NADPH-cytochrome c reductase (20%) and cytochrome b(5) were considerably less. Intraperitoneal administration of CS(2) (100mg/kg) to rats pretreated wtih phenobarbitone or 3-methylcholanthrene resulted in similar losses, but the rate of destruction was greater with cytochrome P-450 than with cytochrome P-448. At 12h after intraperitoneal injection of CS(2) to non-pretreated rats, a new cytochrome (P-448) appeared. Rat liver microsomal preparations incubated with CS(2) in the presence of NADPH and O(2) resulted in loss of cytochrome P-450 and mixed-function-oxidase activity directly related to the concentration of CS(2) (10-100mum) and to the period of incubation. Addition of EDTA (1mm) completely inhibited this destruction of cytochrome P-450 by CS(2)in vitro. Addition of CS(2) to liver microsomal preparations resulted in moderate increases in the K(s) values for type-I or type-II substrates, but these were insufficient to account for the inhibition of the mixed-function oxidases. We therefore suggest that desulphuration of CS(2) leads to binding of the S to cytochrome P-450, denaturation of cytochrome P-450 to cytochrome P-420, and ultimately to destruction of these cytochromes by autoxidation.
| S-EPMC1162543 | biostudies-other
Project description:Pretreatment of hamsters with 3-methylcholanthrene (100mg/kg body wt.) 24h before death did not appreciably change the extent of N-oxide formation when hepatic microsomal preparations were incubated with NN-dimethylaniline as substrate. In contrast, the N-hydroxylation of 2-acetamidofluorene was increased severalfold in hepatic microsomal preparations from pretreated animals. Under these conditions there were no appreciable changes in cytochrome P-450 content and NADPH-cytochrome c reductase activity. On the basis of these comparative data, it is suggested that amine oxidase is not involved in N-hydroxylation of 2-acetamidofluorene.
| S-EPMC1166069 | biostudies-other
Project description:ObjectiveIn this study, the effect of lomitapide, a microsomal triglyceride transfer protein inhibitor, on the cardiovascular function in obesity was investigated.MethodsEight-week-old C57BL/6 mice were fed with high-fat diet for 12 weeks in the presence and absence of lomitapide. Lomitapide was administered by gavage (1 mg/kg/d) during the last 2 weeks of high-fat feeding. Body weight, blood glucose, body composition, and lipid profile were determined. Vascular function and endothelial function markers were studied in the aorta and mesenteric resistance arteries.ResultsLomitapide treatment reduced body weight in mice with obesity. Blood glucose, percentage of fat mass, total cholesterol, and low-density lipoprotein levels were significantly reduced, and the percentage of lean mass was significantly increased after lomitapide treatment. The vascular response to sodium nitroprusside in the aorta and mesenteric arteries was similar among groups. However, the vascular response to acetylcholine was improved in the treated group. This was associated with decreased levels of vascular endoplasmic reticulum stress, inflammation, and oxidative stress.ConclusionsTreatment with lomitapide attenuated the increase in body weight in mice with obesity and restored the lipid profile and vascular function. These effects were accompanied by a decrease in inflammation and oxidative stress.
| S-EPMC8957593 | biostudies-literature
Project description:The Fall Armyworm, Spodoptera frugiperda (Lepidoptera, Noctuidae), is a serious migratory pest. After invading China in 2019, the species was established as a year-round breeding population in most of the southern provinces. The area of winter maize in this region has been increasing due to the huge demand of fresh maize consumption, which is potentially at risk from this invasive pest, although the growth and development of S. frugiperda in the region's changing climate is unclear, particularly with rising temperatures at night. Here, we used the highest daytime temperatures of 27 °C, 24 °C, 20 °C and decreased these by 2, 4 and 6 °C to reflect the range of nighttime temperatures indicative of winter conditions in a warming climate to evaluate the effect of increasing night temperatures on the growth and development of S. frugiperda. Results show that the survival of larvae and pupae significantly declined with daytime temperatures declining and the nighttime temperature range increasing. Significant developmental effects were observed across all daytime-nighttime temperature treatments, except for adults. Additionally, there were significant interaction effects for all stages, except the egg stage, and generation time. The development rate increased with the increasing daytime temperatures and nighttime temperatures, except for the intermediate treatments (Group II). The uniformity of pupation and emergence times were higher under high daytime temperatures and nighttime temperature treatments. Predictions of FAW development and warnings to local farmers need to be adjusted to take into account the more rapid development when nighttime temperatures increase in the warming climate. These results will support decision makers in developing long-term management strategies for FAW in southern China.
| S-EPMC10971192 | biostudies-literature
Project description:1. Homogenates of insect tissues were assayed for enzymes capable of oxidizing p-nitrotoluene to p-nitrobenzoic acid. 2. Locust fat-body homogenate 10000g supernatant was an effective enzyme and required no added cofactors. 3. Homogenates of other insects or locust organs and 10000g sediment from locust fat-body were not active and inhibited microsomal oxidations carried out by locust fat-body or rabbit liver enzyme. 4. Inhibitory power was high in homogenates of whole flies and of fly heads or thoraces. 5. Inhibition appeared to involve both irreversible inactivation of enzyme and the removal of essential cofactors.
| S-EPMC1270271 | biostudies-other
Project description:We report the complete genome sequence of a baculovirus from the moth Spodoptera eridania, the southern armyworm. The genome sequence is 149,090 bp and exhibits the greatest degree of sequence similarity with genomes from alphabaculoviruses isolated from other moths of the genus Spodoptera.
| S-EPMC6346151 | biostudies-literature
Project description:We investigated the mechanisms by which inhibitors of prostaglandin G/H synthase-2 (PGHS-2; known colloquially as COX-2) increase the incidence of myocardial infarction and stroke. These inhibitors are believed to exert both their beneficial and their adverse effects by suppression of PGHS-2-derived prostacyclin (PGI(2)) and PGE(2). Therefore, the challenge remains to identify a mechanism whereby PGI(2) and PGE(2) expression can be suppressed while avoiding adverse cardiovascular events. Here, selective inhibition, knockout, or mutation of PGHS-2, or deletion of the receptor for PGHS-2-derived PGI(2), was shown to accelerate thrombogenesis and elevate blood pressure in mice. These responses were attenuated by COX-1 knock down, which mimics the beneficial effects of low-dose aspirin. PGE(2) biosynthesis is catalyzed by the coordinate actions of COX enzymes and microsomal PGE synthase-1 (mPGES-1). We show that deletion of mPGES-1 depressed PGE(2) expression, augmented PGI(2) expression, and had no effect on thromboxane biosynthesis in vivo. Most importantly, mPGES-1 deletion affected neither thrombogenesis nor blood pressure. These results suggest that inhibitors of mPGES-1 may retain their antiinflammatory efficacy by depressing PGE(2), while avoiding the adverse cardiovascular consequences associated with PGHS-2-mediated PGI(2) suppression.
| S-EPMC1435722 | biostudies-literature
Project description:Purpose of reviewHomozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by high levels of Low density lipoprotein cholesterol (LDL-C); overt, early-onset atherosclerotic cardiovascular disease (ASCVD); and premature cardiovascular events and mortality. Lomitapide is a first-in-class microsomal triglyceride transfer protein inhibitor for the treatment of HoFH. This review provides an update on data emerging from real-world studies of lomitapide following on from its pivotal phase 3 clinical trial in HoFH.Recent findingsRecent registry data have confirmed that HoFH is characterized by delayed diagnosis, with many patients not receiving effective therapy until they are approaching the age when major adverse cardiovascular events may occur. Data from case series of varying sizes, and from a 163-patient registry of HoFH patients receiving lomitapide, have demonstrated that lomitapide doses are lower and adverse events less severe than in the phase 3 study. Lomitapide enables many patients to reach European Atherosclerosis Society LDL-C targets. Some patients are able to reduce frequency of lipoprotein apheresis or, in some cases, stop the procedure altogether-unless there is significant elevation of lipoprotein (a). Modelling analyses based on historical and clinical trial data indicate that lomitapide has the potential to improve cardiovascular outcomes and survival in HoFH. Real-world clinical experience with lomitapide has shown the drug to be effective with manageable, less marked adverse events than in formal clinical studies. Event modelling data suggest a survival benefit with lomitapide in HoFH.
| S-EPMC7303073 | biostudies-literature